NAD+ and Post-Viral Fatigue: What the Studies Tried
When long COVID emerged, NAD+ was one of the first things proposed for it, and the reasoning was better than most. The fatigue of post-viral illness looks, at the cellular level, like an energy problem — mitochondria that do not recover, a metabolism stuck in a low gear — and NAD+ sits at the center of cellular energy. Several small trials followed. This page is what they found, written for the person who is still tired a year on and has read that NAD+ might be the answer.
The main page covers NAD+ in general. The fatigue workup covers the far more common causes of persistent tiredness after forty-five, which this page assumes have been looked for.
Why NAD+ was hypothesized
Post-viral fatigue — whether after COVID-19, glandular fever, or the older syndrome now called ME/CFS — shares a metabolic signature in the studies that have looked: impaired mitochondrial function in muscle and immune cells, a shift toward less efficient energy pathways, persistent low-grade inflammation, and, in several reports, lower NAD+ in cells. SARS-CoV-2 in particular activates enzymes (the PARPs) that consume NAD+ as part of the antiviral response, and laboratory work early in the pandemic showed infected cells depleting NAD+ and recovering when it was replaced.
Put together, the hypothesis was: the virus drains NAD+; the drain persists or leaves damage; replacing NAD+ restores energy metabolism and relieves the fatigue. It is a coherent story, and it is the reason NAD+ went into trials rather than staying on message boards.
What the trials tried
The human studies are few, small, and mostly of oral precursors rather than NAD+ itself.
A randomized, placebo-controlled trial of a combination product containing NAD+ precursors and other supplements in people with long COVID found improvements in fatigue scores over several weeks — but the product had multiple ingredients, so the contribution of NAD+ could not be separated out.
A Norwegian trial of nicotinamide riboside in long COVID, and a related program in ME/CFS, reported mixed results: some improvement in fatigue and cognitive measures in some analyzes, no difference from placebo in others, and no clear objective change. Earlier, a small trial in ME/CFS of an NAD+-related supplement (NADH, the reduced form, with CoQ10) found modest improvements in fatigue and biochemical markers over eight weeks in a few dozen participants.
No trial has tested NAD+ injection — subcutaneous or IV — for long COVID or post-viral fatigue in a controlled design. The IV NAD+ long-COVID protocols offered by some clinics are uncontrolled, and their reported outcomes are testimonials.
The honest read
Encouraging, unproven, and not specific. The trials are too small to be conclusive, the positive signals are modest and inconsistent, and the best-designed of them are ambiguous. Nothing in them suggests NAD+ is harmful in this population, and nothing in them establishes that it works. The mechanism remains plausible; the evidence has not yet caught up with it, and it may not.
Two further things worth knowing. First, post-viral fatigue improves in most people over time regardless of treatment, which makes uncontrolled reports and testimonials especially unreliable — the person who felt better after three months of NAD+ may have felt better after three months. Second, the fatigue of long COVID is heterogeneous: some of it is deconditioning, some dysautonomia, some sleep disruption, some mood, some persistent inflammation, and a single cellular intervention is unlikely to address all of it.
What must come first
A diagnosis, and a workup. Long COVID is a diagnosis of exclusion, and a person who is persistently tired after an infection needs the same assessment as anyone with persistent fatigue — thyroid, iron, B12, blood count, blood sugar, liver and kidney function, a sleep history, a mood screen, and in the post-COVID context a look for the specific complications the infection can leave: heart and lung involvement, autonomic dysfunction (the racing heart on standing, the dizziness), and post-exertional malaise, which changes what exercise advice is safe. The fatigue workup covers the general assessment; the post-COVID-specific evaluation belongs with a primary clinician or a post-COVID clinic, and we refer there.
We do not diagnose or manage long COVID. What we can do, for a person who has that diagnosis and has been assessed, is offer NAD+ as one of the plausible, low-risk, unproven things to try alongside the management their clinic recommends — with the expectations this page sets, a defined trial period, and the honesty to stop if nothing changes.
Frequently asked questions
The trials are small, mostly of oral precursors, and mixed — modest improvements in some, no difference from placebo in others. Plausible and unproven. No controlled trial of NAD+ injection exists for it.
Because the virus activates enzymes that consume NAD+, and post-viral fatigue shows a mitochondrial energy signature NAD+ sits at the center of. The mechanism is reasonable; the evidence has not confirmed it.
A small older trial of NADH with CoQ10 in ME/CFS found modest improvements over eight weeks; more recent nicotinamide riboside work has been ambiguous. Nothing conclusive.
IV NAD+ protocols for long COVID are uncontrolled and their outcomes are testimonials. If you try NAD+, do it after diagnosis and workup, with a defined trial period.
No. Long COVID needs a diagnosis of exclusion and a post-COVID-specific evaluation, which belongs with your primary clinician or a post-COVID clinic. We refer, and we can offer NAD+ alongside that care where appropriate.
A defined period agreed with your clinician, judged by how you feel. Post-viral fatigue improves over time on its own, so an honest assessment weighs that too.
Where this fits in your plan
The fatigue workup comes first; post-COVID-specific assessment sits with your primary or specialist clinic. The NAD+ Injection page covers what we offer for those who reach it, with the caveats this page adds.
We measure first. Then we act.
References
- Heer CD et al. Coronavirus infection and PARP expression dysregulate the NAD metabolome: an actionable component of innate immunity. Journal of Biological Chemistry 2020;295:17986–17996.
- Block T, Kuo J. Rationale for nicotinamide adenine dinucleotide (NAD+) metabolome disruption as a pathogenic mechanism of post-acute COVID-19 syndrome. Clinical Pathology 2022;15:2632010X221106986.
- Forsyth LM et al. Therapeutic effects of oral NADH on the symptoms of patients with chronic fatigue syndrome. Annals of Allergy, Asthma & Immunology 1999;82:185–191.
- Castro-Marrero J et al. Effect of coenzyme Q10 plus nicotinamide adenine dinucleotide supplementation on maximum heart rate after exercise testing in chronic fatigue syndrome. Clinical Nutrition 2016;35:826–834.
- Back toNAD+ Injection
- Fatigue after 45: the workupThe short list of measurable causes behind persistent fatigue, and the red flags that need in-person care.Read
- NAD+ for brain fogThe mouse studies are striking and the human trials are small. What NAD+ has actually been shown to do for cognition, what "brain fog" usually is, and where NAD+ sits once the reversible causes are checked.Read
- Why so tired after 50?Age alone does not explain persistent fatigue at 50. The seven causes that account for most of it, ranked by how often they turn out to be the answer.Read
How we write and review our content
ACT 2 Health provides clinician-led care. Treatments are available only to eligible patients following clinical evaluation and within applicable regulations. This content is educational and is not medical advice. Individual results vary.
Compounded medication. Prepared by a licensed compounding pharmacy under a prescription written for you. Compounded medications are not FDA-approved, are not reviewed by the FDA for safety or effectiveness, and are not equivalent to or interchangeable with any branded product. Prescribed only when a licensed provider determines it is medically appropriate.
Care is delivered via telemedicine by healthcare professionals licensed in the state where the patient is located. Services are available only in states where our providers are licensed.